The association of fibrocystic breast disease with endometrial histopathological results in abnormal uterine bleeding

Endometrial pathology in fibrocystic breast disease



Fibrocystic breast disease, Endometrial pathology, Hyperplasia, Polyp


Background/Aim: Fibrocystic breast disease (FBD) is the most frequent benign breast disease. Increased estrogen and decreased progesterone concentrations are thought to be involved in the pathogenesis of FBD. But there is insufficient data on benign breast disease and endometrial pathology. This study evaluates the association between FBD and endometrial pathology in women complaining of abnormal uterine bleeding.

Methods: This study was designed as a retrospective case-control study. The medical records of women who had endometrial sampling for abnormal uterine bleeding between 2018 and 2020 were evaluated. Patients with FBD were included in the study group, while the first patients who had endometrial sampling after patients with FBD and without breast disease were recruited as the control group. Demographic, laboratory data, and endometrial histopathological results were obtained from hospital records and compared between the groups.

Results: In total, 250 women (106 women with FBD and 144 without breast disease) were recruited for the study. There was no statistically significant difference in mean age, gravidity, parity, and BMI between FBD and control groups. Endometrial hyperplasia without atypia (19.8% versus 10.5%, respectively, P = 0.037) and endometrial polyp (12.2% versus 4.8%, respectively, P = 0.033) were found to be significantly increased in patients with FBD than women without the disease. There was no statistically significant difference in terms of other histopathological results between the groups.

Conclusion: Evaluation of the endometrium for abnormal uterine bleeding is essential for early diagnosis and treatment of endometrial pathology, especially for endometrial cancer. In this study, we found that women with FBD have an increased risk for endometrial hyperplasia and endometrial polyp. As endometrial hyperplasia is a precursor lesion for endometrial cancer, clinicians should pay attention to and investigate menstrual bleeding abnormalities of women with FBD and should not delay the evaluation of the endometrium.


Download data is not yet available.


Milosevic ZC, Nadrljanski MM, Milovanovic ZM, Gusic NZ, Vucicevic SS, Radulovic OS. Breast dynamic contrast enhanced MRI: fibrocystic changes presenting as a non-mass enhancement mimicking malignancy. Radiol Oncol. 2017;51(2):130-6. DOI:

Gorins A, Denis C. Effects of progesterone and progestational hormones on the mammary gland. Arch Anat Cytol Pathol. 1995;43:28–35.

Stachs A, Stubert J, Reimer T, Hartmann S. Benign Breast Disease in Women. Dtsch Arztebl Int. 2019;116:565–74. DOI:

Albers JR, Hull SK, Wesley RM. Abnormal uterine bleeding. Am Fam Physician. 2004;69:1915-26.

Sweet MG, Schmidt-Dalton TA, Weiss PM, Madsen KP. Evaluation and management of abnormal uterine bleeding in premenopausal women. Am Fam Physician. 2012;85:35-43.

Heller DS. Pathologic basis for abnormal uterine bleeding with organic uterine pathologies. Menopause. 2011;18:412-5. DOI:

Farquhar CM, Lethaby A, Sowter M, Verry J, Baranyai J. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol. 1999;181:525-9. DOI:

Devit J. Clinical benign disorders of the breast and carcinoma of the breast. Surg Gynecol Obstet. 1981;152:437–40.

Hilton SV, Leopold GR, Olson LK, Willson SA. Real-time breast sonography: Application in 300 consecutive patients. Am J Roentgenol. 1986;147:479–86. DOI:

Wang, DY, Fentiman JS. The epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat. 1985;6:5-36. DOI:

Vorherr H. Fibrocystic breast disease: Pathophysiology, pathomorphology, clinical picture and management. Am J Obstet Gynecol. 1986 Jan;154(1):161-79. DOI:

Brkić M, Vujović S, Ivović M, Gajić MT, Marina L, Ivanišević MF, et al. The role of E2/P ratio in the etiology of fibrocystic breast disease, mastalgia, and mastodynia. Acta Clin Croat. 2018;57:756-61. DOI:

Dogliotti L, Orlandi F, Angeli A. The endocrine basis of benign breast disorders. World J Surg. 1989;13:674–9. DOI:

Sitruk-ware LR, Sterkers N, Mowszowicz I, Mauvais-Jarvis P. Inadequate corpus luteal function in women with benign breast diseases. J Clin Endocrinol Metab. 1977 Apr;44(4):771-4. DOI:

Marchesoni D, Gangemi M, Mozzanega B, Paternoster D, Graziottin A, Maggino T. Inadequate luteal phase and benign breast disease. Clin Exp Obstet Gynecol. 1981;8(4):160-3.

Wypych K, Kuźlik R, Wypych P. Hormonal abnormalities in women with breast cysts. Ginekol Pol. 2002; Nov;73(11):1117-25.

Thalabard JC, Sitruk-Ware R, Kuttenn F, Mauvais-Jarvis P. Endocrine markers in benign breast diseases. Zentralbl Gynakol. 1986;108:354–8.

D’Amelio R, Farris M, Grande S, Feraudo E, Iuliano A, Zichella L. Association between polycystic ovary and fibrocystic breast disease. Gynecol Obstet Invest. 2001;51:134–7. DOI:

Ozkaya Enis, Cakir Evrim, Cinar Mehmet, Kara Fadıl, Baser Eralp, Cakir Caner, et al. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS? Gynecological Endocrinology. 2012;28(6):468–71. DOI:

Mills AM, Longacre TA. Endometrial hyperplasia. Semin Diagn Pathol. 2010 Nov;27(4):199-214. DOI:

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. DOI:

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics CA Cancer J Clin. 2015 Mar;65(2):87-108. DOI:

Donne ML, Alibrandi A, Ciancimino L, Azzerboni A, Chiofalo B, Triolo O. Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings. Oncol Lett. 2013 Apr;5(4):1305-10. DOI:

Lieng M, Istre O, Qvigstad E. Treatment of endometrial polyps: a systematic review. Acta Obstet Gynecol Scand. 2010 Aug;89(8):992-1002. DOI:

Gul A, Ugur M, Iskender C, Zulfikaroglu E, Ozaksit G. Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps and its relationship to clinical parameters. Arch Gynecol Obstet. 2010;281:479. DOI:

Tallini G, Vanni R, Manfioletti G, Kazmierczak B, Faa G, Pauwels P, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest. 2000;80:359. DOI:

Van Bogaert LJ. Clinicopathologic findings in endometrial polyps. Obstet Gynecol. 1988;71:771.

Daniel M, López L, López FO, Molina LGB, Novo PB. Endometrial polyps in obese asymptomatic pre and postmenopausal patients with breast cancer: Is screening necessary? Gynecologic Oncology. 2014;133:56–6. DOI:






Research Article

How to Cite

Vural S, Özdemir O, Sağır M, Soysal Çağanay, Yılmaz Z. The association of fibrocystic breast disease with endometrial histopathological results in abnormal uterine bleeding: Endometrial pathology in fibrocystic breast disease. J Surg Med [Internet]. 2022 Jul. 29 [cited 2024 May 18];6(7):709-12. Available from: